Drug firm Sanofi India today said it has launched diabetes treatment ‘Toujeo’ insulin in the country. The product, which is a next generation basal insulin, is a once-daily long-acting basal analog insulin that improves glycemic control in adults with type 1 and type 2 diabetes.
“The launch of Toujeo reaffirms our strong commitment to expanding Sanofi’s portfolio and to drive better diabetes management in India,” Sanofi India Managing Director N Rajaram said in a statement. Toujeo was first approved in 2015 in the US and since then, it has been approved in over 65 countries. It is a prescription drug and is available in the newly designed SoloSTAR pen.
Low blood sugar or hypoglycemia is a constant fear amongst people on insulin. Toujeo effectively lowers blood glucose, while minimising the risk of hypoglycemia, Sanofi India said. It works by slowly releasing small amounts of insulin to provide continuous glucose-lowering activity that lasts beyond 24 hours, it added. Sanofi India shares were trading up 2.27 per cent at Rs 4,828.75 on BSE.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.